-
Something wrong with this record ?
Temperature-Controlled Catheter Ablation for Paroxysmal Atrial Fibrillation: the QDOT-MICRO Workflow Sttudy
T. Potter, M. Grimaldi, HK. Jensen, J. Kautzner, P. Neuzil, J. Vijgen, A. Natale, SB. Kristiansen, P. Lukac, P. Peichl, V. Y Reddy
Language English Country United States
Document type Journal Article
NLK
Free Medical Journals
from 2008
PubMed Central
from 2008 to 2021
Europe PubMed Central
from 2008
Open Access Digital Library
from 2008-01-01
- Publication type
- Journal Article MeSH
Background: A novel QDOT MICRO (Biosense Webster, Inc., Irvine, CA) catheter with optimized temperature control and microelectrodes was designed to incorporate real-time temperature sensing with contact force detection and microelectrodes to streamline ablation workflow. The QDOT-MICRO feasibility study evaluated the workflow, performance, and safety of temperature-controlled catheter ablation in patients with symptomatic paroxysmal atrial fibrillation with conventional ablation setting. Methods: This was a non-randomized, single-arm, first-in-human study. The primary outcome was pulmonary vein isolation (PVI), confirmed by entrance block after adenosine and/or isoproterenol challenge. Safety outcomes included incidences of early-onset primary adverse events (AEs) and serious adverse device effects (SADEs). Device performance was evaluated via physician survey. Results: All evaluated patients (n = 42) displayed 100% PVI. Two primary AEs (4.8%) were reported: 1 pericarditis and 1 vascular pseudoaneurysm. An additional SADE of localized infection was reported in 1 patient. No stroke, patient deaths, or other unanticipated AEs were reported. Average power delivered was 32.1±4.1 W, with a mean temperature of 40.8°C±1.6°C. Mean procedure (including 20-minute wait), fluoroscopy, and radiofrequency application times were 129.8, 6.7, and 34.0 minutes, respectively. On device performance, physicians reported overall satisfactory performance with the new catheter, with highest scores for satisfaction and usefulness of the temperature indicator. Conclusions: Initial clinical experience with the novel catheter showed 100% acute PVI success and acceptable safety and device performance in temperature-controlled ablation mode. There were no deaths, stroke, or unanticipated AEs. Fluoroscopy and procedural times were short and similar or better than reported for prior generation catheters.
Icahn School of Medicine at Mount Sinai 1 Gustave L Levy Pl New York NY 10029 USA
Institute for Clinical and Experimental Medicine Vídeňská 1958 9 140 21 Prague Czech Republic
Interventional Electrophysiology SCRIPPS Green Hospital San Diego CA 92037 USA
Jessa Ziekenhuis Virga Jesse Stadsomvaart 11 3500 Hasselt Belgium
Na Homolce Hospital Roentgenova 2 150 30 Prague 5 Czech Republic
OLV Hospital Cardiology Department Moorselbaan 164 9300 Aalst Belgium
Ospedale Generale Regionale F Miulli Strada Prov 127 70021 Acquaviva delle Fonti BA Italy
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22001768
- 003
- CZ-PrNML
- 005
- 20220112153715.0
- 007
- ta
- 008
- 220107s2021 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.4022/jafib.20200460 $2 doi
- 035 __
- $a (PubMed)34950350
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Potter, Tom De $u OLV Hospital, Cardiology Department, Moorselbaan 164, 9300 Aalst, Belgium
- 245 10
- $a Temperature-Controlled Catheter Ablation for Paroxysmal Atrial Fibrillation: the QDOT-MICRO Workflow Sttudy / $c T. Potter, M. Grimaldi, HK. Jensen, J. Kautzner, P. Neuzil, J. Vijgen, A. Natale, SB. Kristiansen, P. Lukac, P. Peichl, V. Y Reddy
- 520 9_
- $a Background: A novel QDOT MICRO (Biosense Webster, Inc., Irvine, CA) catheter with optimized temperature control and microelectrodes was designed to incorporate real-time temperature sensing with contact force detection and microelectrodes to streamline ablation workflow. The QDOT-MICRO feasibility study evaluated the workflow, performance, and safety of temperature-controlled catheter ablation in patients with symptomatic paroxysmal atrial fibrillation with conventional ablation setting. Methods: This was a non-randomized, single-arm, first-in-human study. The primary outcome was pulmonary vein isolation (PVI), confirmed by entrance block after adenosine and/or isoproterenol challenge. Safety outcomes included incidences of early-onset primary adverse events (AEs) and serious adverse device effects (SADEs). Device performance was evaluated via physician survey. Results: All evaluated patients (n = 42) displayed 100% PVI. Two primary AEs (4.8%) were reported: 1 pericarditis and 1 vascular pseudoaneurysm. An additional SADE of localized infection was reported in 1 patient. No stroke, patient deaths, or other unanticipated AEs were reported. Average power delivered was 32.1±4.1 W, with a mean temperature of 40.8°C±1.6°C. Mean procedure (including 20-minute wait), fluoroscopy, and radiofrequency application times were 129.8, 6.7, and 34.0 minutes, respectively. On device performance, physicians reported overall satisfactory performance with the new catheter, with highest scores for satisfaction and usefulness of the temperature indicator. Conclusions: Initial clinical experience with the novel catheter showed 100% acute PVI success and acceptable safety and device performance in temperature-controlled ablation mode. There were no deaths, stroke, or unanticipated AEs. Fluoroscopy and procedural times were short and similar or better than reported for prior generation catheters.
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Grimaldi, Massimo $u Ospedale Generale Regionale "F. Miulli" Strada Prov. 127, 70021 Acquaviva delle Fonti BA, Italy
- 700 1_
- $a Jensen, Henrik Kjaerulf $u Department of Cardiology, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, DK-8200 Aarhus N, Denmark
- 700 1_
- $a Kautzner, Josef $u Institute for Clinical and Experimental Medicine, Vídeňská 1958/9, 140 21 Prague, Czech Republic
- 700 1_
- $a Neuzil, Petr $u Na Homolce Hospital, Roentgenova 2, 150 30 Prague 5, Czech Republic
- 700 1_
- $a Vijgen, Johan $u Jessa Ziekenhuis, Virga Jesse, Stadsomvaart 11, 3500 Hasselt, Belgium
- 700 1_
- $a Natale, Andrea $u Texas Cardiac Arrhythmia Institute, St. David's Medical Center 3000 N. IH-35, Suite 720 Austin, TX, 78705, USA $u Interventional Electrophysiology, SCRIPPS Green Hospital, San Diego, CA, 92037, USA
- 700 1_
- $a Kristiansen, Steen Buus $u Department of Cardiology, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, DK-8200 Aarhus N, Denmark
- 700 1_
- $a Lukac, Peter $u Department of Cardiology, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, DK-8200 Aarhus N, Denmark
- 700 1_
- $a Peichl, Petr $u Institute for Clinical and Experimental Medicine, Vídeňská 1958/9, 140 21 Prague, Czech Republic
- 700 1_
- $a Y Reddy, Vivek $u Na Homolce Hospital, Roentgenova 2, 150 30 Prague 5, Czech Republic $u Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Pl, New York, NY, 10029, USA
- 773 0_
- $w MED00165295 $t Journal of atrial fibrillation $x 1941-6911 $g Roč. 13, č. 6 (2021), s. 20200460
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34950350 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20220107 $b ABA008
- 991 __
- $a 20220112153711 $b ABA008
- 999 __
- $a ind $b bmc $g 1745611 $s 1152915
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 13 $c 6 $d 20200460 $e 20210430 $i 1941-6911 $m Journal of atrial fibrillation $n J Atr Fibrillation $x MED00165295
- LZP __
- $a Pubmed-20220107